Skip to main content

Avtozma News

FDA Approves Expanded Indication for Avtozma (tocilizumab-anoh) Intravenous (IV) Formulation in Cytokine Release Syndrome (CRS)

INCHEON, South Korea, Aug. 6, 2025 – Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of...

FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra

JERSEY CITY, N.J., Jan. 30, 2025 – Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

COVID-19, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis

Avtozma patient information at Drugs.com